PBAC positive recommendations for rheumatology drugs PBS listings have been recommended for upadacitinib (Rinvoq) for the treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA). The Pharmaceutical Benefits Advisory Committee (PBAC) made the recommendations that the drug’s price is minimised to the lowest cost biologic DMARD for the indications. At the March meeting the PBAC ...
News in brief: PBS listing for rheumatology drugs; Opioid prescribing falls after doctors sent warning letters; Rheumatologist calls to curb spinal imaging
3 May 2021